Share
Sydney, Australia – Applications for the annual Glaucoma Australia ‘Quinlivan’ Research Grants are now open until 5pm (AEST) 1 July 2021, with the successful recipients being announced on World Sight Day (14 October 2021).
The William A Quinlivan Research Fund was established in 2006 by the late Mr Marcus Quinlivan in honour of his father. Since the funds inception, Glaucoma Australia has committed over $1 million to support high quality glaucoma research in Australia aimed at improving the lives of people with glaucoma through better detection and treatment.
“We are very proud to announce applications are now open for the 2021 round of our ‘Quinlivan’ Research Grants which will continue to fund research that supports our mission to prevent sight loss by increasing early detection and improving treatment adherence.” said Glaucoma Australia CEO Annie Gibbins.
In this next round Glaucoma Australia will invest up to $200,000 and anticipate between 1 and 4 grants will be awarded. All projects will be completed within 3 years of grant allocation and seed fund grants could be used to apply for further funding with NHMRC or other agencies.
Glaucoma Australia is committed to supporting research which focuses on the following four domains:
- Increasing the rate and reliability of early detection of glaucoma
- Improving the treatment and care experience
- Improving the quality and experience of monitoring glaucoma progression
- Providing management tools to improve the quality of life for people with glaucoma
The Glaucoma Australia ‘Quinlivan’ Research Grants are awarded following rigorous evaluation, based largely on the National Health and Medical Research Council (NHMRC) process, along with peer review, to ensure that the successful applicants meet the highest standards. Submissions are reviewed by the Glaucoma Australia Independent Research Panel consisting of internationally recognised experts in glaucoma research including the fields of Ophthalmology, Optometry and Pharmacy.
To apply please visit www.glaucoma.org.au/i-treat-glaucoma/quinlivan-research-grants
For more information
Annie Gibbins
CEO glaucoma Australia
(02) 9411 7722
ceo@glaucoma.org.au
AI is set to revolutionise the way doctors and patients interact with ophthalmic healthcare, with several published diagnostic AI models already boasting performance on par with eye specialists in the detection of diabetic retinopathy, macular degeneration, and glaucoma.
A/Prof Owen Siggs, recipient of the Glaucoma Australia ‘Quinlivan’ Research Grant in 2022 is now 18 months into his research into the Genomic Risk Stratification to improve glaucoma suspect triage in rural primary care.
Macquarie University researchers have identified a gene therapy that could help treat glaucoma, with potential applications for other neurodegenerative conditions such as Alzheimer’s disease.